Pancreatic Cancer Research

ResearcherFudan UniversityActive in the last 2 years

Li Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0148-6474; OpenAlex author ID A5022933142. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. CircHPCAL1 promotes the progression of pancreatic cancer via the regulation of STEAP2. Co-author DOI 10.1002/ctm2.70501↗
  2. Circular RNA LIPH promotes pancreatic cancer glycolysis and progression through sponge miR-769-3p and interaction with GOLM1. Co-author DOI 10.1002/ctm2.70003↗
  3. Lost miR-141 and upregulated TM4SF1 expressions associate with poor prognosis of pancreatic cancer: regulation of EMT and angiogenesis by miR-141 and TM4SF1 vi… Last author DOI 10.1080/15384047.2019.1702401↗
  4. Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis. Last author DOI 10.3892/mmr.2019.10321↗
  5. Overexpression of serine/threonine-protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of … Last author DOI 10.3892/mmr.2015.3434↗
  6. LPS induced miR-181a promotes pancreatic cancer cell migration via targeting PTEN and MAP2K4. Last author DOI 10.1007/s10620-014-3049-y↗
  7. hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Co-author DOI 10.3892/ijo.2013.2189↗
  8. MiR‑203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting Survivin. Last author DOI 10.3892/mmr.2013.1504↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaomeng He · 2 shared papers, 2024–2025 · strength 0.41
  2. Jin Wang · 2 shared papers, 2024–2025 · strength 0.41
  3. Dong Xu · 4 shared papers, 2014–2020 · strength 0.25
  4. Jianqing Xu · 1 shared paper, 2025 · strength 0.22
  5. Di Yang · 1 shared paper, 2025 · strength 0.22
  6. Wenchuan Wu · 1 shared paper, 2025 · strength 0.22
  7. Qingguang Wang · 4 shared papers, 2013–2015 · strength 0.20
  8. Yong An · 3 shared papers, 2013–2020 · strength 0.20
  9. Yan Ma · 1 shared paper, 2024 · strength 0.19
  10. Zhihui Bai · 1 shared paper, 2024 · strength 0.19
  11. Jiajia Wu · 1 shared paper, 2019 · strength 0.11
  12. Jingjing Zhang · 1 shared paper, 2015 · strength 0.05
  13. Min Tu · 1 shared paper, 2015 · strength 0.05
  14. Dong Xu · 1 shared paper, 2013 · strength 0.05
  15. Jianhui Liu · 1 shared paper, 2014 · strength 0.05
  16. Yi Zhu · 1 shared paper, 2014 · strength 0.04
  17. Yi Miao · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.